Compare · BSX vs MDT
BSX vs MDT
Side-by-side comparison of Boston Scientific Corporation (BSX) and Medtronic plc. (MDT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. BSX focuses on Medical/Dental Instruments, while MDT focuses on Biotechnology: Electromedical & Electrotherapeutic Apparatus.
- MDT is the larger of the two at $102.71B, about 1.2x BSX ($83.97B).
- Over the past year, BSX is down 46.1% and MDT is down 5.7% - MDT leads by 40.4 points.
- MDT has been more active in the news (22 items in the past 4 weeks vs 3 for BSX).
- Both have 25 recent analyst ratings on file.
- Company
- Boston Scientific Corporation
- Medtronic plc.
- Price
- $56.52-1.89%
- $80.00-1.23%
- Market cap
- $83.97B
- $102.71B
- 1M return
- -8.85%
- -7.06%
- 1Y return
- -46.14%
- -5.71%
- Industry
- Medical/Dental Instruments
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 3
- 22
- Recent ratings
- 25
- 25
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Latest BSX
- Data at Heart Rhythm 2026 highlight key Boston Scientific therapies
- Boston Scientific Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Boston Scientific announces results for first quarter 2026
- SEC Form EFFECT filed by Boston Scientific Corporation
- SEC Form 424B3 filed by Boston Scientific Corporation
- Boston Scientific downgraded by Raymond James with a new price target
- Boston Scientific announces conference call discussing first quarter 2026 results
- Amendment: SEC Form S-4/A filed by Boston Scientific Corporation
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and efficacy endpoints
Latest MDT
- FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy
- Chief Accounting Officer Blomquist Denise L. was granted 1,508 units of Ordinary Shares and covered exercise/tax liability with 318 units of Ordinary Shares, increasing direct ownership by 10% to 13,262 units (SEC Form 4)
- Director Nabel Elizabeth G was granted 2,111 units of Ordinary Shares and covered exercise/tax liability with 207 units of Ordinary Shares, increasing direct ownership by 11% to 19,584 units (SEC Form 4)
- Director Powell Kendall J was granted 2,111 units of Ordinary Shares and covered exercise/tax liability with 207 units of Ordinary Shares, increasing direct ownership by 4% to 51,380 units (SEC Form 4)
- Director Lofton Kevin E was granted 2,111 units of Ordinary Shares and covered exercise/tax liability with 207 units of Ordinary Shares, increasing direct ownership by 23% to 10,140 units (SEC Form 4)
- Director Jellison William R was granted 1,444 units of Ordinary Shares, increasing direct ownership by 29% to 6,444 units (SEC Form 4)
- Director Lee Joon Sup was granted 1,803 units of Ordinary Shares (SEC Form 4)
- Director Lewis Gregory P was granted 2,111 units of Ordinary Shares and covered exercise/tax liability with 207 units of Ordinary Shares, increasing direct ownership by 49% to 5,754 units (SEC Form 4)
- Director Hogan Randall J was granted 2,111 units of Ordinary Shares and covered exercise/tax liability with 207 units of Ordinary Shares, increasing direct ownership by 4% to 48,998 units (SEC Form 4)
- Director Groetelaars John P was granted 1,444 units of Ordinary Shares (SEC Form 4)